Search companies

Live

ALTERITY THERAPEUTICS LIMITED (ASX: ATH)

Health care · News and insights

Price unavailable

Latest ATH announcements

Alterity Therapeutics CEO to Present at Bell Potter Healthcare Conference

2026-11-12 · Health care

ATH: $0.250 -9.09% · MC: $57M

Alterity Therapeutics CEO David Stamler will present at the virtual Bell Potter Healthcare Conference on 19 November, with an archived webcast to be made available on the company’s website. Alterity is preparing a pivotal Phase 3 trial of ATH434 for multiple system atrophy, following confirmation of the trial design and regulatory pathway in its recent quarterly update.

Updated 2026-11-12 11:29
Share
SourcesAlterity to Present at Bell Potter Healthcare Conference
Comments

Alterity Advances ATH434 Phase 3 Preparations After FDA Trial Design Agreement

2026-10-30 · Health care

ATH: $0.265 +1.92% · MC: $57M

Alterity Therapeutics says FDA meeting minutes confirmed agreement on the proposed Phase 3 trial design for ATH434 in multiple system atrophy, and operational preparations are underway. The FDA indicated that a single pivotal trial plus confirmatory evidence could support approval, although approval is not assured. Alterity is evaluating funding and partnering alternatives and ended the quarter with approximately $41 million in cash, including a tax refund and proceeds from option exercises. A new US patent for ATH434 extends protection to 2045.

Updated 2026-10-30 12:23
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments